Syngenta has acquired Novartis' natural products and genetic strains assets to enhance its biologicals research capabilities and support sustainable agricultural practices.

Target Information

Syngenta has made a strategic move to bolster its biologicals research and development by acquiring the natural products and genetic strains assets from Novartis. This acquisition includes the Novartis Natural Products and Biomolecular Chemistry team, enhancing Syngenta's capabilities in agricultural innovation. While Novartis retains exclusive rights to the repository for pharmaceutical applications, the transfer provides Syngenta with access to valuable resources for agricultural research.

This acquisition is accompanied by Syngenta's inauguration of a new cutting-edge production facility located in Orangeburg, South Carolina. This state-of-the-art facility represents Syngenta's first full-scale production site for agricultural biologicals in the United States, responding to the increasing demand for innovative and sustainable agricultural solutions across the North and Latin American markets.

Industry Overview in the USA

The agricultural industry in the United States is experiencing a significant shift towards sustainability, with biologicals emerging as a crucial component of modern farming practices. Biologicals, including biocontrols and biostimulants, off